Administer triamcinolone with caution

Article

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration.

The persistence of intraocular pressure (IOP) elevation following treatment with intravitreal triamcinolone acetonide (IVTA) means that it should only be used after careful consideration, according to the results of a study published online ahead of print by Clinical Ophthalmology.

M. Selim kocabora and co-workers from the Vakif Gureba Education and Research Hospital, Istanbul, Turkey reviewed the records of 122 patients (147 eyes) who had undergone IVTA treatment between 2003 and 2006.

The mean IOP following IVTA injection was statistically significantly higher than pre-injection IOP. Important IOP elevations were observed mostly in the first and second months. In 40 eyes (27.7%), topical anti-glaucomatous therapy was required and seven later required surgical intervention to lower IOP.

The researchers think that IVTA should be administered only after careful planning.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.